Product Information
GS INF IBUPROFEN 50 MG/1.25 ML is a generic product labeled by L. Perrigo Company, priced at $0.3253 per ML under NDC 00113005705. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 16, 1998.
Strength
50 mg/1.25mL
Manufacturer
L. Perrigo CompanyNDC
00113005705
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
IBUPROFENApproval Type
Generic (ANDA)
FDA Application
ANDA075217FDA Approved
12/16/1998
On Market Since
2/8/2000
Pharmacological Classes
Price Statistics
The NADAC for GS INF IBUPROFEN 50 MG/1.25 ML has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 18.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.3253 per ML |
|---|---|
| All-time high | $0.3440 (Mar 15, 2023) |
| All-time low | $0.2035 (Nov 18, 2020) |
| 52-week high | $0.3307 |
| 52-week low | $0.3050 |
| Median price | $0.2549 |
| Average price | $0.2634 |
| Largest weekly change | +45.2% (Dec 23, 2020) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 29% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
L. Perrigo Company manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ibuprofen market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GS INF IBUPROFEN 50 MG/1.25 ML?
The current National Average Drug Acquisition Cost (NADAC) for GS INF IBUPROFEN 50 MG/1.25 ML, manufactured by L. Perrigo Company, is $0.3253 per ML (NDC 00113005705), effective Sep 30, 2026.
How has the price of GS INF IBUPROFEN 50 MG/1.25 ML changed over time?
Over the history we have for it, the NADAC for GS INF IBUPROFEN 50 MG/1.25 ML has risen 18.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for GS INF IBUPROFEN 50 MG/1.25 ML?
Since Nov 28, 2013, the NADAC for GS INF IBUPROFEN 50 MG/1.25 ML has ranged from a low of $0.2035 (Nov 18, 2020) to a high of $0.3440 (Mar 15, 2023), with a median of $0.2549 per ML.
Are there cheaper alternatives to GS INF IBUPROFEN 50 MG/1.25 ML?
Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, INFANT IBUPROFEN 50 MG/1.25 ML, is $0.2324 per ML — about 29% below GS INF IBUPROFEN 50 MG/1.25 ML.
Who manufactures GS INF IBUPROFEN 50 MG/1.25 ML?
GS INF IBUPROFEN 50 MG/1.25 ML (NDC 00113005705) is labeled by L. Perrigo Company, and CMS classifies it as a generic product.